tradmap

CCCC C4 Therapeutics, Inc.

$3.74 -1.06%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

C4 Therapeutics, Inc. (CCCC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $460 million. Shares last traded at $3.74, 27.6% below their 52-week high. Over the past year the stock is up 45.5%. Net profit margin is -289.4%, below the peer median of 5.3%. Revenue grew 1.0% year over year.

Market Cap
$460M
Shares Out
123.0M
EPS (TTM)
$-2.50
P/E Ratio
P/S Ratio
13.13
P/B Ratio
1.86
Dividend / Share
Dividend Yield
52-Week High
$5.17
52-Week Low
$1.70
Volume
129,230
Avg Vol (3m)
167,517.857

Performance

1W
-8.56%
1M
+3.60%
3M
-10.10%
6M
+23.43%
YTD
+93.78%
1Y
+45.53%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.04
SMA (50)
$3.92
SMA (200)
$3.04
Price vs SMA50
-4.69%
Price vs SMA200
+23.09%
ATR (14)
$0.23

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$35M
Net Income
$-101M
Gross Margin
Operating Margin
-319.0%
Net Margin
-289.4%
Return on Equity
-41.0%
Return on Assets
-28.2%
Current Ratio
5.45
Debt / Equity
0.00
Revenue Growth (YoY)
+1.0%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.38 2026-08-11
Q1 2026 $-0.20 2026-05-12
FY 2025 $-1.27 2026-02-26
Q3 2025 $-1.18 2025-11-06
Q2 2026 $-0.74 2026-08-11
Q1 2026 $-0.37 2026-05-12

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CCCC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
13.13 / 19.49 med
-33% discount
Net margin vs peers
-289.4% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.